What were building Neurophorol to enable (research-stage endpoints): receptor/pathway profiling + SAR learning neuroimmune and inflammation readouts oxidative stress / resilience markers reproducible preclinical validation workflows Were opening collaboration discussions with teams who can help validate and translate this platform responsibly: (Universities, Biotech companies, Tribal communities, and Investors) CB1/CB2 functional assays + signaling bias analytical chemistry (LCMS/NMR) + stability profiling neuroimmune models (microglia), biomarkers, preclinical design ADME/PK and translational study frameworks If you work in this space, comment NEUROPHOROL or DM your capability stack
reverse, TTTTCGTGGCCGACTACTCT) and non-CpG primers: (forward, TGCAGCCAGTAGTTACAAGC
GZ: Writing original draft
The microspheres vary in size, ranging from submicron to 1000 micron diameters
However, the expression of GPx1 has been reported to be down-regulated in thyroid cancer [44], colorectal cancer [45, 46], and gastric cancer [47], whereas GPx1 has been demonstrated to play an oncogenic role in kidney cancer [48], pancreatic cancer [49], and laryngeal squamous cell carcinoma [50]